122 related articles for article (PubMed ID: 21196440)
1. HER2 and response to anthracycline-based neoadjuvant chemotherapy in breast cancer.
Yao L; Liu Y; Li Z; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xie Y
Ann Oncol; 2011 Jun; 22(6):1326-1331. PubMed ID: 21196440
[TBL] [Abstract][Full Text] [Related]
2. CD10 expression as a potential predictor of pathological complete response in ER-negative and triple-negative breast cancer patients treated with anthracycline-based neoadjuvant chemotherapy.
Dimitrov G; Shousha S; Troianova P
Exp Mol Pathol; 2024 Feb; 135():104885. PubMed ID: 38281565
[TBL] [Abstract][Full Text] [Related]
3. Tumor-stroma ratio is associated with Miller-Payne score and pathological response to neoadjuvant chemotherapy in HER2-negative early breast cancer.
Hagenaars SC; de Groot S; Cohen D; Dekker TJA; Charehbili A; Meershoek-Klein Kranenbarg E; Duijm-de Carpentier M; Pijl H; Putter H; Tollenaar RAEM; Kroep JR; Mesker WE;
Int J Cancer; 2021 Sep; 149(5):1181-1188. PubMed ID: 34043821
[TBL] [Abstract][Full Text] [Related]
4. Neoadjuvant chemotherapy with or without anthracyclines in combination with single HER2-targeted therapy in HER2-positive breast cancer.
Gupta A; Gogia A; Deo S; Sharma DN; Mathur S; Sagiraju HKR
Cancer Treat Res Commun; 2023; 36():100741. PubMed ID: 37453371
[TBL] [Abstract][Full Text] [Related]
5. Pathological responses and long-term outcome analysis after neoadjuvant chemotheraphy in breast cancer patients from Kuwait over a period of 15 years.
Krishnan Y; Alawadhi SA; P S S; Gopal M; Thuruthel S
Ann Saudi Med; 2013; 33(5):443-50. PubMed ID: 24188937
[TBL] [Abstract][Full Text] [Related]
6. Relationship between IHC4 score and response to neo-adjuvant chemotherapy in estrogen receptor-positive breast cancer.
Sheri A; Smith IE; Hills M; Jones RL; Johnston SR; Dowsett M
Breast Cancer Res Treat; 2017 Jul; 164(2):395-400. PubMed ID: 28447240
[TBL] [Abstract][Full Text] [Related]
7. Complete pathological response in patients with HER2 positive breast cancer treated with neoadjuvant therapy in Colombia.
Rodríguez M; González DM; El-Sharkawy F; Castaño M; Madrid J
Biomedica; 2023 Sep; 43(3):396-405. PubMed ID: 37871573
[TBL] [Abstract][Full Text] [Related]
8. Effect of HER2-low expression on neoadjuvant efficacy in operable breast cancer.
Yi X; Hu S; Ma M; Huang D; Zhang Y
Clin Transl Oncol; 2024 Apr; 26(4):880-890. PubMed ID: 37702827
[TBL] [Abstract][Full Text] [Related]
9. Association between pathologic complete response and biochemical indicators after neoadjuvant therapy for HER2-positive breast cancer.
Chen W; Zhang J; Li F; Chen Z; Li J; Lu DL
World J Surg Oncol; 2024 May; 22(1):126. PubMed ID: 38725003
[TBL] [Abstract][Full Text] [Related]
10. Neoadjuvant Chemotherapy of Taxanes With or Without Anthracyclines in Different Molecular Subtypes of Breast Cancer: A Propensity Score Matching Study.
Xiao J; Wang T; Yi J; Huang M; Yan C; Ling R
Clin Breast Cancer; 2023 Dec; 23(8):882-893. PubMed ID: 37833133
[TBL] [Abstract][Full Text] [Related]
11. Prognosis and influencing factors of ER-positive, HER2-low breast cancer patients with residual disease after neoadjuvant chemotherapy: a retrospective study.
Tang L; Jiang L; Shu X; Jin Y; Yu H; Liu S
Sci Rep; 2024 May; 14(1):11761. PubMed ID: 38783028
[TBL] [Abstract][Full Text] [Related]
12. Expression of secreted protein acidic and rich in cysteine (SPARC) in breast cancer and response to neoadjuvant chemotherapy.
Lindner JL; Loibl S; Denkert C; Ataseven B; Fasching PA; Pfitzner BM; Gerber B; Gade S; Darb-Esfahani S; Sinn BV; Huober J; Engels K; Tesch H; Karn T; Pommerenke F; Liedtke C; Untch M; Müller V; Rack B; Schem C; von Minckwitz G
Ann Oncol; 2015 Jan; 26(1):95-100. PubMed ID: 25355716
[TBL] [Abstract][Full Text] [Related]
13. Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL--CALGB 150007/150012, ACRIN 6657.
Esserman LJ; Berry DA; DeMichele A; Carey L; Davis SE; Buxton M; Hudis C; Gray JW; Perou C; Yau C; Livasy C; Krontiras H; Montgomery L; Tripathy D; Lehman C; Liu MC; Olopade OI; Rugo HS; Carpenter JT; Dressler L; Chhieng D; Singh B; Mies C; Rabban J; Chen YY; Giri D; van 't Veer L; Hylton N
J Clin Oncol; 2012 Sep; 30(26):3242-9. PubMed ID: 22649152
[TBL] [Abstract][Full Text] [Related]
14. Ki-67 Change in Anthracyline-containing Neoadjuvant Chemotherapy Response in Breast Cancer.
Yang ZG; Ren LH; Wang F; Wang PL; Wang WY; Lin SY
Curr Med Sci; 2024 Feb; 44(1):156-167. PubMed ID: 38302780
[TBL] [Abstract][Full Text] [Related]
15. Real-world data on neoadjuvant chemotherapy with dual-anti HER2 therapy in HER2 positive breast cancer.
Yang ZJ; Xin F; Chen ZJ; Yu Y; Wang X; Cao XC
BMC Cancer; 2024 Jan; 24(1):134. PubMed ID: 38273267
[TBL] [Abstract][Full Text] [Related]
16. An aCGH classifier derived from BRCA1-mutated breast cancer and benefit of high-dose platinum-based chemotherapy in HER2-negative breast cancer patients.
Vollebergh MA; Lips EH; Nederlof PM; Wessels LFA; Schmidt MK; van Beers EH; Cornelissen S; Holtkamp M; Froklage FE; de Vries EGE; Schrama JG; Wesseling J; van de Vijver MJ; van Tinteren H; de Bruin M; Hauptmann M; Rodenhuis S; Linn SC
Ann Oncol; 2011 Jul; 22(7):1561-1570. PubMed ID: 21135055
[TBL] [Abstract][Full Text] [Related]
17. Predictive markers for pathological complete response (pCR) after neo-adjuvant chemotherapy in HER2-positive breast carcinoma.
Van Bockstal MR; Dano H; Benhaddi N; Dubois D; Vanderveken J; Van Marcke C; Vandermeulen A; Duhoux FP; Vernaeve H; Berlière M; Galant C
Histol Histopathol; 2024 Feb; 39(2):153-164. PubMed ID: 37204204
[TBL] [Abstract][Full Text] [Related]
18. Cytoplasmic Cyclin E Expression Predicts for Response to Neoadjuvant Chemotherapy in Breast Cancer.
Karakas C; Francis AM; Ha MJ; Wingate HF; Meena RA; Yi M; Rasaputra KS; Barrera AMG; Arun B; Do KA; Sahin A; Keyomarsi K; Hunt KK
Ann Surg; 2021 Aug; 274(2):e150-e159. PubMed ID: 31436549
[TBL] [Abstract][Full Text] [Related]
19. Clinicopathological response to neoadjuvant therapies and pathological complete response as a biomarker of survival in human epidermal growth factor receptor-2 enriched breast cancer - A retrospective cohort study.
Davey MG; Kerin E; O'Flaherty C; Maher E; Richard V; McAnena P; McLaughlin RP; Sweeney KJ; Barry MK; Malone CM; Wyns W; Soliman O; Miller N; Keane MM; Lowery AJ; Kerin MJ
Breast; 2021 Oct; 59():67-75. PubMed ID: 34171619
[TBL] [Abstract][Full Text] [Related]
20. Prognostic implications of HER2 changes after neoadjuvant chemotherapy in patients with HER2-zero and HER2-low breast cancer.
Kang S; Lee SH; Lee HJ; Jeong H; Jeong JH; Kim JE; Ahn JH; Jung KH; Gong G; Kim HH; Lee S; Lee J; Kim SB
Eur J Cancer; 2023 Sep; 191():112956. PubMed ID: 37473465
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
